Elanix Biotechnologies AG erhält eine Bestätigung der Outperform Empfehlung durch goetzpartners securities

Firma Elanix BiotechnologiesBiotechnik, , , , , , , , , , , , , ,

Outperform Empfehlung nach den Webcast Präsentationen an Investoren am 7.August Empfehlung basiert auf den Geschäfts- und Produktplänen des Elanix Managements Zielpreis der Elanix Aktie nach goetzpartners bleibt bei EUR 6,40 Elanix Biotechnologies AG ("Elanix") informiert heute, dass goetzpartners securities ihre Mehr

Elanix Biotechnologies AG getting confirmation of Outperform Recommendation by goetzpartners securities

Firma Elanix BiotechnologiesBiotechnik, , , , , , , , , , , , , ,

Outperform statement following webcast presentations to investors on 7 August, 2018 Statement is based on commercial roll-out plans presented by Elanix Management Share price target indicated by goetzpartners remains at EUR 6.40 Elanix Biotechnologies AG ("Elanix") has announced today that Mehr

Elanix Biotechnologies AG announces cash capital increase with indirect subscription rights from currently EUR 7,779,139 by up to EUR 777,910 to up to EUR 8,557,049

Firma Elanix BiotechnologiesFinanzen / Bilanzen, , , , , , , , , , , , , ,

. – Subscription period for current shareholders from July 27 to August 10, 2018  – Subscription price for shareholders to be EUR 2.75 – Management explaining planned usage of capital raised and future milestones Elanix Biotechnologies AG ("Elanix"; "Company"), a Mehr